In addition, as one of the EMT regulators, EGFR was also shown to regulate the differentiation and proliferation of osteoblasts, chondrocytes, and osteoclasts, thereby regulating cancer metastasis and bone formation [22], and thus EGFR may be considered as a surrogate marker of prostate cancer dissemination to bones [23], supporting the rationale for the use of EGFR inhibitors for prophylaxis or cure of prostate cancer metastasis [3]. The gene discussed is EGFR; the disease is Familial prostate cancer.